ArticleOncotarget2015
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis.Scientific reports · 2018Pooled it
- Interim PET response of Pola-R-CHP predicts outcome in previously untreated CD5-positive diffuse large B-cell lymphoma: a multicenter retrospective study.Annals of medicine · 2026Article
- Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.Blood advances · 2026Article
- AI-Enhanced Quantitative IHC Analysis for Prognostic Stratification in Marginal Zone Lymphoma: Development of a Revised MZL-IPI Model.Diagnostics (Basel, Switzerland) · 2026Article
- A site-specific risk stratification model for extranodal diffuse large B-cell lymphoma in the oral cavity and maxillofacial region.Annals of hematology · 2026Article
- Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma.Annals of hematology · 2026Article
- 2026 Update on the Management of Diffuse Large B-Cell Lymphoma.American journal of hematology · 2026Review
- Efficacy and safety of Pola-R-mini-CHP therapy in patients aged ≥80 years with CD5-positive diffuse large B-Cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2026Article
- [Chinese expert consensus on the diagnosis and treatment of CD5-positive diffuse large B-cell lymphoma (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Integration of high-throughput proteomic data and complementary omics layers with PriOmics.Genome research · 2026Article
- CD5-positive diffuse large B-cell lymphoma of the uterus: a Case Report with cytologic findings from uterine cavity drainage and literature review.Frontiers in oncology · 2026Article
- Clinical features and prognosis analysis of patients with follicular lymphoma: a real-world study in China.Annals of hematology · 2025Article
- Unmet needs of patients with intravascular large B-cell lymphoma: three case reports and a literature review.Journal of Zhejiang University. Science. B · 2025Review
- CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy.Cancer biology & medicine · 2025Article
- Treatments and Outcomes of Newly Diagnosed CD5-Positive Diffuse Large B-Cell Lymphoma: A Multi-Institutional Observational Study.Hematological oncology · 2025Observational
- Improving access to chimeric antigen receptor T-cells for refractory or relapsing diffuse large B cell lymphoma therapy in Asia.Discover oncology · 2025Review
- Long-term remission in a patient with NK/T cell intravascular lymphoma with autologous hematopoietic cell transplantation.Journal of clinical and experimental hematopathology : JCEH · 2025Article
- Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression.OncoTargets and therapy · 2025Review
- The association between NADPH oxidase (NOX) polymorphisms with immunohistochemistry and survival in diffuse large B cell lymphoma patients.Annals of hematology · 2025Article
- PDLIM1, a novel miR-3940-5p target, regulates the malignant progression of diffuse large B-cell lymphoma.Cancer biology & therapy · 2024Article
Corrections and comments
- Erratum issuedErratum: Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.2015 · Nagarajan, Lalitha [Added]
Authors and funding
30 authors at 20 institutions in 9 countries.
Funding
Abstract
CD5 is a pan-T-cell surface marker and is rarely expressed in diffuse large B-cell lymphoma (DLBCL). Large-scale studies of de novo CD5+ DLBCL are lacking in Western countries. In this study by the DLBCL Rituximab-CHOP Consortium, CD5 was expressed in 5.5% of 879 DLBCL patients from Western countries. CD5+ DLBCL was associated with higher frequencies of >1 ECOG performance status, bone marrow involvement, central nervous system relapse, activated B-cell-like subtype, Bcl-2 overexpression, and STAT3 and NF-κB activation, whereas rarely expressed single-stranded DNA-binding protein 2 (SSBP2), CD30 or had MYC mutations. With standard R-CHOP chemotherapy, CD5+ DLBCL patients had significantly worse overall survival (median, 25.3 months vs. not reached, P< .0001) and progression-free survival (median, 21.3 vs. 85.8 months, P< .0001) than CD5- DLBCL patients, which was independent of Bcl-2, STAT3, NF-κB and the International Prognostic Index. Interestingly, SSBP2 expression abolished the prognostic significance of CD5 expression, suggesting a tumor-suppressor role of SSBP2 for CD5 signaling. Gene-expression profiling demonstrated that B-cell receptor signaling dysfunction and microenvironment alterations are the important mechanisms underlying the clinical impact of CD5 expression. This study shows the distinctive clinical and biological features of CD5+ DLBCL patients in Western countries and underscores important pathways with therapeutic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.